2018 Community- Acquired Pneumonia (CAP) Drug Development- Pipeline Analysis Report
Community Acquired Pneumonia (CAP) is one of the lower respiratory tract infections affecting around 150 million people worldwide annually. Bacterial pathogens responsible for CAP include Streptococcus pneumoniae, atypical bacteria, and Haemophilus influenza. Despite antimicrobial therapy advancements, Pneumonia is observed to be a leading cause of death.
The disease is acquired from community and not from hospital related system. As the condition largely resembles that of flu, diagnosis of CAP is challenging. High fever, chest pain, dyspnea, cough, myalgia, arthralgia are key symptoms.
Community Acquired Pneumonia pipeline comprises of 16 drugs under active development as of April 2018. Of these, 3 drugs are in Phase 1 and 4 drugs in phase 2, 3 drugs in Phase 3. Further, 2 drugs are in Pre-clinical stage and 1 drug in research phase. Three drugs are in pre-registration stage.
30 companies are developing the pipeline for Community Acquired Pneumonia. Of this, Melinta Therapeutics, Inc. has highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Enzyme inhibitors and Protein synthesis inhibitors.
One compound has been awarded orphan drug status for Community Acquired Pneumonia.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Community Acquired Pneumonia (CAP) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Community Acquired Pneumonia (CAP) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Community Acquired Pneumonia (CAP) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
The disease is acquired from community and not from hospital related system. As the condition largely resembles that of flu, diagnosis of CAP is challenging. High fever, chest pain, dyspnea, cough, myalgia, arthralgia are key symptoms.
Community Acquired Pneumonia pipeline comprises of 16 drugs under active development as of April 2018. Of these, 3 drugs are in Phase 1 and 4 drugs in phase 2, 3 drugs in Phase 3. Further, 2 drugs are in Pre-clinical stage and 1 drug in research phase. Three drugs are in pre-registration stage.
30 companies are developing the pipeline for Community Acquired Pneumonia. Of this, Melinta Therapeutics, Inc. has highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Enzyme inhibitors and Protein synthesis inhibitors.
One compound has been awarded orphan drug status for Community Acquired Pneumonia.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Community Acquired Pneumonia (CAP) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Community Acquired Pneumonia (CAP) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Community Acquired Pneumonia (CAP) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 COMMUNITY ACQUIRED PNEUMONIA- COMPANY WISE PIPELINE ANALYSIS
3.1 BioAegis Therapeutics, Inc. PIPELINE, H1 2018
3.2 Biotest AG PIPELINE, H1 2018
3.3 ioGenetics, LLC PIPELINE, H1 2018
3.4 KYORIN Pharmaceutical Co.,Ltd PIPELINE, H1 2018
3.5 LASCCO SA. PIPELINE, H1 2018
3.6 Melinta Therapeutics, Inc. PIPELINE, H1 2018
3.7 Nabriva Therapeutics plc PIPELINE, H1 2018
3.8 Pamlico Biopharma, Inc PIPELINE, H1 2018
3.9 Paratek Pharmaceuticals, Inc. PIPELINE, H1 2018
3.10 ProThera Biologics LLC PIPELINE, H1 2018
3.11 Spero Therapeutics, Inc. PIPELINE, H1 2018
3.12 TaiGen Biotechnology Co., Ltd. PIPELINE, H1 2018
3.13 Tetraphase Pharmaceuticals Inc. PIPELINE, H1 2018
3.14 TiGenix NV PIPELINE, H1 2018
3.15 Wockhardt Ltd PIPELINE, H1 2018
4 COMMUNITY ACQUIRED PNEUMONIA DRUG SNAPSHOTS
4.1 RECOMBINANT HUMAN PLASMA GELSOLIN DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 TRIMODULIN DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 DBAF301 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 KRP-AM1977 DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 CAL02 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 SPR994 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 DELAFLOXACIN DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 SOLITHROMYCIN DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 LEFAMULIN DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial Details
4.10 PNEUMOMAB DRUG DETAILS
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.11 OMADACYCLINE DRUG DETAILS
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 PLASMA-DERIVED INTER-ALPHA INHIBITOR PROTEINS DRUG DETAILS
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 NEMONOXACIN DRUG DETAILS
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.14 TP-271 DRUG DETAILS
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.14.5 Trial Details
4.15 CX-611 DRUG DETAILS
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial Details
4.16 NAFITHROMYCIN DRUG DETAILS
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial Details
5 RECENT DEVELOPMENTS IN COMMUNITY ACQUIRED PNEUMONIA PIPELINE
5.1 Study on Adjunctive Corticosteroids in Community Acquired Pneumonia- 2018
5.2 Nabriva Therapeutics to Present Lefamulin Study Results in Community-acquired Bacterial Pneumonia- 2018
5.3 Paratek to Present Omadacycline Study Results at ECCMID- 2018
5.4 Cardiome Announces Xydalba and Zevtera Details- 2018
5.5 University of Texas MD Anderson Cancer Center Announces Reduced use of Antibiotics in CAP- 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 COMMUNITY ACQUIRED PNEUMONIA- COMPANY WISE PIPELINE ANALYSIS
3.1 BioAegis Therapeutics, Inc. PIPELINE, H1 2018
3.2 Biotest AG PIPELINE, H1 2018
3.3 ioGenetics, LLC PIPELINE, H1 2018
3.4 KYORIN Pharmaceutical Co.,Ltd PIPELINE, H1 2018
3.5 LASCCO SA. PIPELINE, H1 2018
3.6 Melinta Therapeutics, Inc. PIPELINE, H1 2018
3.7 Nabriva Therapeutics plc PIPELINE, H1 2018
3.8 Pamlico Biopharma, Inc PIPELINE, H1 2018
3.9 Paratek Pharmaceuticals, Inc. PIPELINE, H1 2018
3.10 ProThera Biologics LLC PIPELINE, H1 2018
3.11 Spero Therapeutics, Inc. PIPELINE, H1 2018
3.12 TaiGen Biotechnology Co., Ltd. PIPELINE, H1 2018
3.13 Tetraphase Pharmaceuticals Inc. PIPELINE, H1 2018
3.14 TiGenix NV PIPELINE, H1 2018
3.15 Wockhardt Ltd PIPELINE, H1 2018
4 COMMUNITY ACQUIRED PNEUMONIA DRUG SNAPSHOTS
4.1 RECOMBINANT HUMAN PLASMA GELSOLIN DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 TRIMODULIN DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 DBAF301 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 KRP-AM1977 DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 CAL02 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 SPR994 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 DELAFLOXACIN DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 SOLITHROMYCIN DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 LEFAMULIN DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial Details
4.10 PNEUMOMAB DRUG DETAILS
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.11 OMADACYCLINE DRUG DETAILS
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 PLASMA-DERIVED INTER-ALPHA INHIBITOR PROTEINS DRUG DETAILS
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 NEMONOXACIN DRUG DETAILS
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.14 TP-271 DRUG DETAILS
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.14.5 Trial Details
4.15 CX-611 DRUG DETAILS
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial Details
4.16 NAFITHROMYCIN DRUG DETAILS
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial Details
5 RECENT DEVELOPMENTS IN COMMUNITY ACQUIRED PNEUMONIA PIPELINE
5.1 Study on Adjunctive Corticosteroids in Community Acquired Pneumonia- 2018
5.2 Nabriva Therapeutics to Present Lefamulin Study Results in Community-acquired Bacterial Pneumonia- 2018
5.3 Paratek to Present Omadacycline Study Results at ECCMID- 2018
5.4 Cardiome Announces Xydalba and Zevtera Details- 2018
5.5 University of Texas MD Anderson Cancer Center Announces Reduced use of Antibiotics in CAP- 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Community Acquired Pneumonia Pipeline by Phase, H1- 2018
Figure 2: Community Acquired Pneumonia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Community Acquired Pneumonia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Community Acquired Pneumonia Pipeline by Phase, H1- 2018
Figure 2: Community Acquired Pneumonia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Community Acquired Pneumonia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Community Acquired Pneumonia Pipeline by Phase, H1- 2018
Table 2: Community Acquired Pneumonia Pipeline by Companies, H1- 2018 (1)
Table 3: Community Acquired Pneumonia Pipeline by Mechanism of Action, H1- 2018
Table 4: BioAegis Therapeutics, Inc. Community Acquired Pneumonia Pipeline, H1- 2018
Table 5: Biotest AG - Community Acquired Pneumonia Pipeline, H1- 2018
Table 6: ioGenetics, LLC - Community Acquired Pneumonia Pipeline, H1- 2018
Table 7: KYORIN Pharmaceutical Co.,Ltd - Community Acquired Pneumonia Pipeline, H1- 2018
Table 8: LASCCO SA.- Community Acquired Pneumonia Pipeline, H1- 2018
Table 9: Melinta Therapeutics, Inc.- Community Acquired Pneumonia Pipeline, H1- 2018
Table 10: Nabriva Therapeutics plc - Community Acquired Pneumonia Pipeline, H1- 2018
Table 11: Pamlico Biopharma, Inc- Community Acquired Pneumonia Pipeline, H1- 2018
Table 12: Paratek Pharmaceuticals, Inc. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 13: ProThera Biologics LLC - Community Acquired Pneumonia Pipeline, H1- 2018
Table 14: Spero Therapeutics, Inc. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 15: TaiGen Biotechnology Co., Ltd. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 16: Tetraphase Pharmaceuticals Inc. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 17: TiGenix NV - Community Acquired Pneumonia Pipeline, H1- 2018
Table 18: Wockhardt Ltd- Community Acquired Pneumonia Pipeline, H1- 2018
Table 1: Community Acquired Pneumonia Pipeline by Phase, H1- 2018
Table 2: Community Acquired Pneumonia Pipeline by Companies, H1- 2018 (1)
Table 3: Community Acquired Pneumonia Pipeline by Mechanism of Action, H1- 2018
Table 4: BioAegis Therapeutics, Inc. Community Acquired Pneumonia Pipeline, H1- 2018
Table 5: Biotest AG - Community Acquired Pneumonia Pipeline, H1- 2018
Table 6: ioGenetics, LLC - Community Acquired Pneumonia Pipeline, H1- 2018
Table 7: KYORIN Pharmaceutical Co.,Ltd - Community Acquired Pneumonia Pipeline, H1- 2018
Table 8: LASCCO SA.- Community Acquired Pneumonia Pipeline, H1- 2018
Table 9: Melinta Therapeutics, Inc.- Community Acquired Pneumonia Pipeline, H1- 2018
Table 10: Nabriva Therapeutics plc - Community Acquired Pneumonia Pipeline, H1- 2018
Table 11: Pamlico Biopharma, Inc- Community Acquired Pneumonia Pipeline, H1- 2018
Table 12: Paratek Pharmaceuticals, Inc. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 13: ProThera Biologics LLC - Community Acquired Pneumonia Pipeline, H1- 2018
Table 14: Spero Therapeutics, Inc. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 15: TaiGen Biotechnology Co., Ltd. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 16: Tetraphase Pharmaceuticals Inc. - Community Acquired Pneumonia Pipeline, H1- 2018
Table 17: TiGenix NV - Community Acquired Pneumonia Pipeline, H1- 2018
Table 18: Wockhardt Ltd- Community Acquired Pneumonia Pipeline, H1- 2018
